Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02241720 · ClinicalTrials.gov registry record · Phase 2
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02241720: Clinical Trial Phase 2 study, sponsored by University of Utah.
NCT02241720 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02241720, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Primary Outcome
Patients had disease assessed by CT scans. Stable Disease is defined by any response better than Progression as defined by RECIST 1.1. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Interventions
- DRUG regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Why NCT02241720 stopped before completion
NCT02241720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which regorafenib is the first listed.
NCT02241720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02241720 about?
NCT02241720 is a clinical study titled "Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers". Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
What is the current status of trial NCT02241720?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2014-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02241720?
The interventions under investigation include: regorafenib (DRUG).
Who is sponsoring clinical trial NCT02241720?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02241720's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia